{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
phenyl aminosalicylate
to a specific field?
Status:
Investigational
Source:
NCT00852839: Phase 2 Interventional Completed Dry Mouth Associated With Sjogren's Syndrome
(2009)
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Compound 552-02 is a potent, selective inhibitor of epithelial sodium channels that is effective in enhancing mucociliary clearance and is well tolerated when administered as a single dose by inhalation aerosol in normal healthy adult volunteers. Parion Sciences was developing 552 02 for the treatment of xerostomia, cystic fibrosis, chronic bronchitis, chronic obstructive pulmonary disease, radiation injuries. Compound 552-02 was specifically designed for aerosol delivery to the pulmonary system as a more selective, potent, long-acting ENaC blocker to promote an expansion in ASL volume, with or without hypertonic saline. Compound 552-02 was selected from a series of novel ENaC blockers to
produce a selective block on airway epithelial sodium channels, with a potency up to 2 orders of magnitude greater than
amiloride. 552-02 blocked the majority (95%) of Isc, with a calculated IC50 value of 7 nM. Drug development was discontinued.
Status:
Investigational
Source:
INN:profexalone [INN]
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Profexalone is an oxazolidinone derivative patented by Delalande S. A. as anticonvulsive, muscle-relaxant, antidepressive, anti-inflammatory, and analgesic compound.
Class (Stereo):
CHEMICAL (ACHIRAL)
Glicetanile is a derivative of sulphonamides (antibacterial sulfa drugs). It has antihyperglycemic activity. The compound is metabolized and eliminated by the body rapidly after both oral and intravenous administration, and therefore prevents adverse hypoglycemic effects.
Class (Stereo):
CHEMICAL (ABSOLUTE)
Glenvastatin (HR780) is a synthetic HMG-CoA reductase (HMGCR) inhibitor. Like other statins, glenvastatin shows very low systemic bioavailability due to an extensive first pass effect at the intestinal and/or hepatic level. This is a positive trait, since the liver is the target organ for statins. Evidence has been found that glenvastatin protects the vascular endothelium from oxidant stress and inhibits the migration and proliferation of smooth muscle cells. In rabbits, long-term treatment with glenvastatin reduces the plasma cholesterol level, and decreases the liver cholesterol contents. There are no results of clinical trials for glenvastatin.
Class (Stereo):
CHEMICAL (RACEMIC)
Draquinolol is a cardioselective beta-adrenoceptor antagonist with a long duration of action in vivo. The long duration of action of draquinolol in vivo is due to the formation of a tight complex with beta 1-adrenoceptors. Draquinolol reduced an exercise tachycardia.
Class (Stereo):
CHEMICAL (ACHIRAL)
Etabenzarone is an anti-inflammatory and anticoagulant agent.
Class (Stereo):
CHEMICAL (ACHIRAL)
Lorcinadol is an analgesic agent.
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
Ragaglitazar (DRF 2725, NNC 61-0029) is phenoxazine analog of phenyl propanoic acid having dual (PPARα and PPARγ) agonist property intended to restore insulin sensitivity and correct diabetic dyslipidemia. PPAR-α is highly expressed in liver and muscle and upon activation leads to decreases in plasma triglycerides and increases in HDL cholesterol levels. PPAR-γ activation leads to enhancement of glucose uptake in skeletal muscles and adipose tissue. Ragaglitazar provided the glycemic control that was comparable with that of pioglitazone and, compared with placebo, provided a significant improvement in the lipid profile.
Status:
Investigational
Source:
NCT00606697: Phase 2 Interventional Completed Sleep Initiation and Maintenance Disorders
(2007)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Vofopitant (previously known as GR205171), a tetrazole-derivative, was developed as a neurokinin1 receptor antagonist. Vofopitant was studied in clinical trials phase II for the treatment of primary insomnia and posttraumatic stress disorder. However, these studies were discontinued due to lack of effectiveness. In addition, vofopitant participated in phase I for patients with bipolar disorder. However, this study was terminated because of the slow recruitment; trial unlikely to reach completion.
Class (Stereo):
CHEMICAL (ACHIRAL)
Glicondamide is a derivative of sulphonamides (antibacterial sulfa drugs). It acts by increasing the release of insulin from pancreatic beta cells, resulting in lower blood glucose levels.
